GT Biopharma, Inc. — Form D

GT Biopharma, Inc. of SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2017-09-14. The offering totals $4.5M, of which $4.5M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (25)

NameRoleLocation
Kathleen Clarence-SmithDirectorWashington, DC
Kathleen Clarence-SmithExecutive OfficerWashington, DC
Anshuman DubeDirectorLas Vegas, NV
Michael BreenDirectorSAN FRANCISCO, CA
Michael BreenExecutive OfficerSAN FRANCISCO, CA
Alan UrbanExecutive OfficerSAN FRANCISCO, CA
Hilary KramerDirectorSAN FRANCISCO, CA
Charles CasamentoDirectorSAN FRANCISCO, CA
Andrew RitterDirectorSAN FRANCISCO, CA
Bruce WendelDirectorSan Francisco, CA
Rajesh ShrotriyaDirectorSan Francisco, CA
Steven WeldonDirectorBeverly Hills, CA
Steven WeldonExecutive OfficerBeverly Hills, CA
Anthony CataldoDirectorBeverly Hills, CA
Anthony CataldoExecutive OfficerBeverly Hills, CA
Kathleen J Clarence-SmithDirectorTAMPA, FL
Kathleen J Clarence-SmithExecutive OfficerTAMPA, FL
Anthony J CataldoDirectorTAMPA, FL
Jon B BonfiglioDirectorTAMPA, FL
Raymond B UrbanskiExecutive OfficerTAMPA, FL
Peter B KienerDirectorTAMPA, FL
Geoffrey B DavisDirectorTAMPA, FL
David SaloffDirectorBeverly Hills, CA
Kenneth EatonDirectorBeverly Hills, CA
Kenneth EatonExecutive OfficerBeverly Hills, CA

Other filings by this issuer (10)

FiledFormOfferingSold
2025-05-28D$20.0M
2025-05-27D$6.0M$6.0M
2025-03-07D$1.3M$1.3M
2020-07-23D/A$5.6M
2020-06-12D$2.4M
2018-08-17D$5.1M$5.1M
2018-02-06D$7.1M$7.1M
2015-07-27D$1.5M$500K
2015-03-16D$3.0M$2.0M
2014-07-31D$1.4M$1.4M

More